NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE248485 Query DataSets for GSE248485
Status Public on Mar 28, 2024
Title Effects of Antifibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis [IPF_PBMC]
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Two antifibrotic drugs, pirfenidone (PFD) and nintedanib (NTD), are currently used to treat idiopathic pulmonary fibrosis (IPF). Peripheral blood mononuclear cells are immunocompetent cells that can predispose to those within the lungs and orchestrate cell-cell interactions associated with IPF pathogenesis. We employed RNA sequencing to examine the transcriptome signature in bulk peripheral blood mononuclear cells of patients with IPF and the effects of antifibrotic drugs on these signatures. Differentially expressed genes (DEGs) were analyzed in patients with IPF and healthy controls, before and after antifibrotic treatment. Enrichment analysis suggested that fatty acid elongation interferes with profibrotic TGF-β/ signaling and production of oxidative stress since treatment with NTD upregulated the elongation enzymes ELOVL6 and ELOVL7. Treatment with PFD downregulated COL1A1 which produces wound-healing collagens, as activated monocyte-derived macrophages during tissue damage participate in the production of collagen, type I, and alpha 1. Plasminogen activator inhibitor-1 (PAI-1) regulates wound healing by inhibiting plasmin-mediated matrix metalloproteinases activation, and inhibition of PAI-1 activity attenuates lung fibrosis. DEGs analysis suggested that both PFD and NTD upregulated SERPINE1 which in turn regulates PAI-1 activity. This study detected different DEGs as a result of PFD and NTD treatments, suggesting different mechanistic roles for the two antifibrotic drugs.
 
Overall design To investigate the pathogenesis of IPF in PBMCs, we compared IPF (n=6) and healthy control (n=6) samples by RNA-seq.
Then, to investigate the effects of antifibrotic drugs in PBMCs, we compared samples before and after administration of PFD (n=3) and NTD (n=3), respectively, by RNA-seq.
 
Contributor(s) Ishii D, Kawasaki T, Sato H, Tatsumi K, Imamoto T, Yoshioka K, Abe M, Hasegawa Y, Ohara O, Suzuki T
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Nov 22, 2023
Last update date Mar 28, 2024
Contact name Takeshi Kawasaki
E-mail(s) kawatake@chiba-u.jp
Phone +81-43-222-7171
Organization name Chiba University
Department Respirology
Street address 1-8-1, Inohana, Chuoku
City Chiba
ZIP/Postal code 2608670
Country Japan
 
Platforms (1)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
Samples (18)
GSM7915821 Healthy control [DK22269_01]
GSM7915822 Healthy control [DK22269_03]
GSM7915823 Healthy control [DK22269_04]
Relations
BioProject PRJNA1044112

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE248485_count_DK21068B.xlsx 1.4 Mb (ftp)(http) XLSX
GSE248485_count_DK21222.xlsx 1.2 Mb (ftp)(http) XLSX
GSE248485_count_DK22190.xlsx 1.8 Mb (ftp)(http) XLSX
GSE248485_count_DK22269.xlsx 1.4 Mb (ftp)(http) XLSX
GSE248485_rpm_DK21068.xlsx 1.6 Mb (ftp)(http) XLSX
GSE248485_rpm_DK21222.xlsx 1.3 Mb (ftp)(http) XLSX
GSE248485_rpm_DK22190.xlsx 2.2 Mb (ftp)(http) XLSX
GSE248485_rpm_DK22269.xlsx 1.6 Mb (ftp)(http) XLSX
SRA Run SelectorHelp
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap